Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis
Objectives: The definition of circulatory impairment in the premature infant is controversial. Current research suggests overdiagnosis and overtreatment. We aimed to analyse which biomarkers move clinicians to initiate cardiovascular treatment (CVT). The prognostic capacity for adverse outcome (deat...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-05-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fped.2019.00212/full |
id |
doaj-c251d5e029aa44c5a7ee1f1d9daa1fd6 |
---|---|
record_format |
Article |
spelling |
doaj-c251d5e029aa44c5a7ee1f1d9daa1fd62020-11-25T01:32:14ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602019-05-01710.3389/fped.2019.00212440664Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective AnalysisMaría Carmen Bravo0Paloma López-Ortego1Laura Sánchez2Rosario Madero3Fernando Cabañas4Fernando Cabañas5Armin Koch6Héctor Rojas-Anaya7Heike Rabe8Adelina Pellicer9Department of Neonatology, La Paz University Hospital, Madrid, SpainDepartment of Neonatology, La Paz University Hospital, Madrid, SpainDepartment of Neonatology, La Paz University Hospital, Madrid, SpainDivision of Statistics, La Paz University Hospital, Madrid, SpainDepartment of Neonatology, La Paz University Hospital, Madrid, SpainDepartment of Pediatrics and Neonatology, Quironsalud Madrid University Hospital, Madrid, SpainMedizinische Hochschule Hannover, Institut für Biometrie, Hannover, GermanyAcademic Department of Paediatrics, Brighton and Sussex Medical School, Brighton, United KingdomAcademic Department of Paediatrics, Brighton and Sussex Medical School, Brighton, United KingdomDepartment of Neonatology, La Paz University Hospital, Madrid, SpainObjectives: The definition of circulatory impairment in the premature infant is controversial. Current research suggests overdiagnosis and overtreatment. We aimed to analyse which biomarkers move clinicians to initiate cardiovascular treatment (CVT). The prognostic capacity for adverse outcome (death and/or moderate-severe brain damage by cranial ultrasound at term equivalent) of these biomarkers was evaluated.Study Design: Retrospective data analysis from preterm infants enrolled in a placebo-controlled trial on dobutamine for low superior vena cava (SVC) flow, who showed normal SVC flow within the first 24 h (not randomized). Five positive biomarkers were considered: MABP < gestational age (GA)-1 mmHg; MABP < GA-5 mmHg; lactate > 4 mmol/L; BE < −9 mmol/L; SVC flow <51 ml/kg/min.Results:Ninety eight infants formed the study cohort. Thirty six received CVT (2–95 h). Logistic regression models adjusted for gestational age showed a positive association between CVT and the risk of death or moderate-severe abnormal cranial ultrasound at term equivalent [(OR 5.2, 95%CI: 1.8–15.1) p = 0.002]. MABP < GA-1 mmHg and lactate > 4 mmol/L were the most prevalent biomarkers at start of treatment. Low BE, high serum lactate and low SVC flow at first echocardiography showed a trend toward being associated with adverse outcome, although not statistically significant.Conclusions: Low blood pressure and high lactate are the most prevalent biomarkers used for CVT prescription. Lactic acidosis and low SVC flow early after birth showed a trend toward being associated with adverse outcome. These findings support using a combination of biomarkers for inclusion in a placebo-controlled trial on CVT during transitional circulation.https://www.frontiersin.org/article/10.3389/fped.2019.00212/fulltransitional circulationcirculatory impairmentcardiovascular treatmenthypotensionpreterm |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
María Carmen Bravo Paloma López-Ortego Laura Sánchez Rosario Madero Fernando Cabañas Fernando Cabañas Armin Koch Héctor Rojas-Anaya Heike Rabe Adelina Pellicer |
spellingShingle |
María Carmen Bravo Paloma López-Ortego Laura Sánchez Rosario Madero Fernando Cabañas Fernando Cabañas Armin Koch Héctor Rojas-Anaya Heike Rabe Adelina Pellicer Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis Frontiers in Pediatrics transitional circulation circulatory impairment cardiovascular treatment hypotension preterm |
author_facet |
María Carmen Bravo Paloma López-Ortego Laura Sánchez Rosario Madero Fernando Cabañas Fernando Cabañas Armin Koch Héctor Rojas-Anaya Heike Rabe Adelina Pellicer |
author_sort |
María Carmen Bravo |
title |
Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis |
title_short |
Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis |
title_full |
Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis |
title_fullStr |
Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis |
title_full_unstemmed |
Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis |
title_sort |
validity of biomarkers of early circulatory impairment to predict outcome: a retrospective analysis |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pediatrics |
issn |
2296-2360 |
publishDate |
2019-05-01 |
description |
Objectives: The definition of circulatory impairment in the premature infant is controversial. Current research suggests overdiagnosis and overtreatment. We aimed to analyse which biomarkers move clinicians to initiate cardiovascular treatment (CVT). The prognostic capacity for adverse outcome (death and/or moderate-severe brain damage by cranial ultrasound at term equivalent) of these biomarkers was evaluated.Study Design: Retrospective data analysis from preterm infants enrolled in a placebo-controlled trial on dobutamine for low superior vena cava (SVC) flow, who showed normal SVC flow within the first 24 h (not randomized). Five positive biomarkers were considered: MABP < gestational age (GA)-1 mmHg; MABP < GA-5 mmHg; lactate > 4 mmol/L; BE < −9 mmol/L; SVC flow <51 ml/kg/min.Results:Ninety eight infants formed the study cohort. Thirty six received CVT (2–95 h). Logistic regression models adjusted for gestational age showed a positive association between CVT and the risk of death or moderate-severe abnormal cranial ultrasound at term equivalent [(OR 5.2, 95%CI: 1.8–15.1) p = 0.002]. MABP < GA-1 mmHg and lactate > 4 mmol/L were the most prevalent biomarkers at start of treatment. Low BE, high serum lactate and low SVC flow at first echocardiography showed a trend toward being associated with adverse outcome, although not statistically significant.Conclusions: Low blood pressure and high lactate are the most prevalent biomarkers used for CVT prescription. Lactic acidosis and low SVC flow early after birth showed a trend toward being associated with adverse outcome. These findings support using a combination of biomarkers for inclusion in a placebo-controlled trial on CVT during transitional circulation. |
topic |
transitional circulation circulatory impairment cardiovascular treatment hypotension preterm |
url |
https://www.frontiersin.org/article/10.3389/fped.2019.00212/full |
work_keys_str_mv |
AT mariacarmenbravo validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT palomalopezortego validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT laurasanchez validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT rosariomadero validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT fernandocabanas validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT fernandocabanas validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT arminkoch validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT hectorrojasanaya validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT heikerabe validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis AT adelinapellicer validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis |
_version_ |
1725082433808760832 |